Drug intelligence / Profile preview

Propyless

Development stage: Unknown
Lead developer: Karo Healthcare
Modality: Small Molecules
Administration: Topical

Overview

**Propyless** is a Swedish over-the-counter topical emollient medicinal product containing propylene glycol 200 mg/g in a cutaneous emulsion. It is indicated for treatment of dry skin of various causes. Propylene glycol acts primarily as a humectant, increasing water retention in the stratum corneum; the emulsion base provides additional skin-conditioning and protective barrier support. The product has limited antimicrobial activity against certain fungi and bacteria and is marketed by Karo Healthcare. ([docetp.mpa.se](https://docetp.mpa.se/LMF/Propyless%20cutaneous%20emulsion%20PL_09001bee807a7b95.pdf))

Brand names: Propyless

Beyond the preview

Go deeper on Propyless.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propyless.

Explore the full profile